Panel 1 header
Insert text
Form title
Form sub title
Insert text
Panel 3 header
Insert text
Panel 3a header
Insert text
Panel 4 with video
Insert text
Insert text
Meet the newest solution from Cytiva. Made for CAR T, made for what’s next.
We are looking forward to seeing you at ISCT. Join us for an exciting new product reveal over a glass of bubbly on 29 May, 2024 at 6:45 PM on booth #716. If you are working in cell therapy, check out all the sessions showcasing what’s next in autologous CAR T and TCR manufacturing.
Global showcase
Thursday, 30 May, 1:30-1:45 PM
An introduction of the new, end-to-end solution from Cytiva to manufacture autologous CAR T therapies at commercial scale.
Presenters:
Stephanie Bourin, Cytiva
Bertrand Foucaut, Cytiva
Corporate session
Thursday 30 May, 6:00-7:00 PM
Deliver what's next: fueling the future of autologous CAR T therapy
Presenters:
Emmanuel Abate, Cytiva
George White, Cytiva
Sadik Kassim, Danaher
Angela Johnson, Cytiva
Mitchel Sivilotti, OmniaBio
Poster
Wednesday, 29 May, 7:00-8:30 PM
End-to-end manufacturing of autologous CAR T cell therapies with a new cell therapy manufacturing platform
Presenters:
Federico Franchi, Cytiva
Marine De Lageneste, Cytiva
New Product Demo on our booth (#716)
Thursday 30 May, 3.15 PM
OmniaBio corporate session
Friday, 31 May, 5:00-6:00 PM
Streamlining your path to market: leveraging the latest CAR T cell technologies and enabling tools
Presenters:
Neil Blackburn, OmniaBio Inc.
Tim Moore, Allogene
Aaron Dulgar-Tulloch, Cytiva
David Shaw, Genentech
Can't make it to ISCT?
Join us on 13 June to discover what’s next in autologous CAR T manufacturing:
Beyond CAR T
"Don't miss our other cell therapy offerings!
Launch and patient access concurrent session
Friday 31 May 2024, 3:45-4:45 PM
Industralizing manufacturing and distribution: collaborating to advance future therapeutics - from innovation to industrialization
Presenter: Martin Westberg, Cytiva
Posters
Wednesday, 29 May. 7:00-8:30 PM
Regulatory T cell expansion in the Xuri™ cell expansion system W25
Presenter: Mojtaba Parvizi, Cytiva
Thursday, 30 May, 6:00-7:30 PM
Closed, semi-automated harvest of iPSC scale-up workflow using the Sepax™ C-Pro with CultureWash protocol
Presenter: Mojtaba Parvizi, Cytiva
Ready to take the next step in your cell therapy career?
Discover our in-person advanced cell therapy course, which provides comprehensive hands-on insights into cell therapy manufacturing under GMP procedures.
RNA-LNP
Are you working on RNA-LNPs? Discover the potential of our solutions from concept to clinic.
Global showcase
Friday 31 May, 12:30-12:45 PM
Ex vivo engineering of primary cells using RNA-lipid nanoparticles and scale-up manufacturing for cell and gene therapies
Presenter: Samuel Clarke, Cytiva
Posters
Wednesday, 29 May, 7:00-8:30 PM
Optimization of multiplex CRISPR-Cas9 editing of human primary T cells using lipid nanoparticles (LNPs) and subsequent off-target evaluation
Presenter: Meenakshi Swaminathan, Cytiva
Wednesday, 29 May, 7:00-8:30 PM
Strategies for producing clinical and commercial RNA-LNP drug products
Presenter: Robert Young, Cytiva
Round table
Wednesday, 29 May, 2:15-3:15 PM
mRNA therapeutics: You’re simply the best, better than all the rest
Presenter: Scott Ripley, Cytiva
Oral abstract presentation
Thursday, 30 May, 3:45-4:45 PM
Efficient gene editing in CD34+ hematopoietic stem and progenitor cells using non-viral lipid nanoparticles
ISCT 2024 Canadian Top Scoring Award
Presenter: Stella Park, Cytiva
Aseptic Filling
Are you interested in Standardized gloveless, robotic, closed isolators?
Global showcase
Thursday 30 May, 1:15-1:30 PM,
New containment solutions for automated aseptic filling for gene therapy
Presenters:
Jim Thompson, West Pharmaceutical Services
Brent Lieffers, Cytiva
Meet our speakers
Emmanuel Abate,
President Genomic Medicine,
Cytiva
Stephanie Bourin,
Senior Product Manager,
Cytiva
Samuel Clarke,
Director R&D,
Cytiva
Marine De Lageneste,
Biology Team Leader,
Cytiva
Aaron Dulgar-Tulloch,
Chief Technology Officer, Genomic Medicine,
Cytiva
Bertrand Foucaut,
Senior Product Manager,
Cytiva
Federico Franchi,
R&D Manager MBO Biology,
Cytiva
Angela Johnson,
Global Regulatory and Compliance Leader,
Cytiva
Sadik Kassim,
Chief Technology Officer,
Danaher
Brent Lieffers
Senior Director of Innovation Advocacy,
Cytiva
Stella Park,
Associate Scientist, Product Development,
Cytiva
Mojtaba Parvizi,
Global Fast Trak Leader — Cell Therapy,
Cytiva
Scott Ripley,
Business Leader, Nucleic Acid Therapeutics and Precision Nanosystems,
Cytiva
Mitchel Sivilotti,
President and Chief Executive Officer,
OmniaBio
Meenakshi Swaminathan,
Associate Scientist, Product Development,
Cytiva
Jim Thompson,
Director of R&D,
West Pharmaceutical Services
Martin Westberg,
Vice President, Cell Therapy,
Cytiva
George White,
Cell Therapy Product Management Leader,
Cytiva
Robert Young,
Senior Engineer, Systems,
Cytiva
Agenda
Wednesday 29 May, 2024
| Time | Event | Venue | Title |
|---|---|---|---|
| 7:00-8:30 PM | Welcome Poster | ??? | End-to-end manufacturing of autologous CAR T cell therapies with a new cell therapy manufacturing platform. |
| 7:00-8:30 PM | Poster | ??? | Regulatory T cell expansion in the Xuri™ cell expansion system W25 |
| 7:00-8:30 PM | Poster | ??? | Optimization of multiplex CRISPR-Cas9 editing of human primary T cells using lipid nanoparticles (LNPs) and subsequent off-target evaluation |
| 7:00-8:30 PM | Poster | ??? | Strategies for producing clinical and commercial RNA-LNP drug products |
Thursday 30 May, 2024
| Time | Event | Venue | Title |
|---|---|---|---|
| 1:15-1:30 PM | Welcome Global showcase | ??? | New containment solutions for automated aseptic filling for gene therapy |
| 1:30-1:45 PM | Global showcase | ??? | An introduction of the new, end-to-end solution from Cytiva to manufacture autologous CAR T therapies at commercial scale |
| 6:00-7:00 PM; | Corporate session | ??? | Deliver what's next: fueling the future of autologous CAR T therapy |
| 6:00-7:30 PM | Poster | ??? | Closed, semi-automated harvest of iPSC scale-up workflow using the Sepax™ C-Pro with CultureWash protocol |
| 6:00-7:30 PM | Oral abstract presentation | ??? | An introduction of the new, end-to-end solution from Cytiva to manufacture autoEfficient gene editing in CD34+ hematopoietic stem and progenitor cells using non-viral lipid nanoparticles |
Friday 31 May, 2024
| Time | Event | Venue | Title |
|---|---|---|---|
| 12:30-12:45 PM | Product showcase | ??? | Ex Vivo Engineering of Primary Cells Using RNA-Lipid Nanoparticles and Scale-Up Manufacturing for Cell and Gene Therapies |
| 3:45-4:45 PM | Launch and patient access concurrent session | ??? | Industrializing manufacturing and distribution |
Excellent performance
Achieve high titers of infectious virus, which you can boost further by using enhancers.
Enhanced product quality
Minimize DNase-resistant host cell DNA inside capsids.
Innovative
Access advances in cell line engineering across the entire portfolio to support transition between cell lines.
Collaborative
Benefit from a comprehensive suite of regulatory support services.
Excellent performance
Achieve high titers of infectious virus, which you can boost further by using enhancers.
Enhanced product quality
Minimize DNase-resistant host cell DNA inside capsids.
Innovative
Access advances in cell line engineering across the entire portfolio to support transition between cell lines.
Collaborative
Benefit from a comprehensive suite of regulatory support services.
Streamlined screening
Efficiently screen multiple assets that target the same tissue type.
Cost-effective approach
Reduce your plasmid costs with single-plasmid transfection compared with triple transfection.
One cell line to clinic
Go to clinic with one cell line and simplify your regulatory asks when you’re targeting the same tissue type across your programs.